This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome
by Zacks Equity Research
AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
by Zacks Equity Research
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.
Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus
by Urmimala Biswas
According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.
J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit
by Zacks Equity Research
J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
by Zacks Equity Research
Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.
Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus
by Zacks Equity Research
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
Is the Tax Repeal Only Glitter and No Gold for MedTech?
by Nabaparna Bhattacharya
While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.
J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status
by Zacks Equity Research
The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
by Zacks Equity Research
Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?
by Zacks Equity Research
ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
by Zacks Equity Research
AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.
Dow 30 Stock Roundup: Cisco Beats, Caterpillar January Sales up 34%
by Swarup Gupta
The Dow rebounded strongly over the first five trading days after entering correction territory last week.
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
by Zacks Equity Research
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.